



Newborn Screening Quality Assurance Program

PROFICIENCY TESTING PROGRAM FOR ANTI-HIV-1 IN DRIED BLOOD SPOTS

Quarterly Report

Quarter 1

February 2011

INTRODUCTION

The Anti-HIV-1 proficiency testing (PT) panel for Quarter 1, 2011 consisted of five individual-matrix dried-blood spot (DBS) specimens representing a variety of serostatuses. HIV antibody screening and confirmatory tests should identify all HIV-positive specimens, regardless of subtype. Method and laboratory performance are evaluated by challenging participants with specimens representing HIV-negative and positive serostatuses.

On January 18, 2011, we sent the Quarter 1 Anti-HIV-1 panel to 27 participants. We received data reports from 24 participating laboratories by the designated deadline date. This report is the outcome of data reported for the Quarter 1, 2011 Anti-HIV-1 PT specimens. This quarterly report is distributed to all participants and to program colleagues upon request.

Each participant was asked to analyze the specimens for anti-HIV-1 using the assay schemes they routinely use and to report for each specimen the screening results along

with results from any confirmatory assays performed for presumptive positives. A final interpretation for each specimen must be submitted to receive a grade.

PARTICIPANTS' RESULTS

Table 1 shows the overall frequency of reported reactive, non-reactive, and indeterminate screening results for specimens 1141-1145.

In Part 1 of the report, Table 2 shows the number of laboratories using each screening method/kit both for the primary and secondary screens.

Table 3 shows the summary of screening errors by method. There was one false positive error.

In Part 2 of the report, Table 4 shows the number of laboratories using each confirmatory method/kit.

Table 5 shows the Reported Frequency of Bands by Western Blot for each of the PT specimens that tested positive for the Anti-HIV-1 screening analysis.

The Quality Assurance Program will ship next quarter's HIV-1 DBS

proficiency testing specimens on April 11, 2011 and the next major allotment of HIV-1 DBS quality control specimens on July 18, 2011.

CONFERENCES AND MEETINGS

2011 National HIV Prevention Conference, Atlanta, Georgia. August 14-17, 2011.

United States Conference on AIDS, Chicago, IL, November 10-13, 2011.

SPOTLIGHT

President Obama's Fiscal Year (FY) 2011 federal budget request, released on February 1, 2011 includes an estimated \$27.2 billion for combined domestic and global HIV/AIDS activities.

Domestic HIV/AIDS is funded at \$20.5 billion and global at \$6.7 billion. The FY 2011 request represents a 4.6% increase (\$1.2 billion) over FY 2010, which totaled \$26 billion.

The Fact sheet on the 2011 budget proposal can be viewed at the following website:

<http://www.kff.org/hivaids/upload/7029-06.pdf>



Direct inquiries to:
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, MS/F43
Atlanta, GA 30341-3724

Quarterly publications for colleagues and participants of the Proficiency Testing Program for Anti-HIV-1 in Dried Blood Spots.

Phone: 770-488-7897
FAX: 770-488-4255
E-mail: NMeredit@cdc.gov

Editor: Nancy Meredith
Production: Connie Singleton



**Anti-HIV-1 PT Report
Quarter 1, 2011**

TABLE 1: Frequency Distribution: Outcome of Final Interpretations (#Labs)

Specimen Number	Expected Results	Reactive	Non-reactive	Indeterminate	Not Reported
1141	Reactive	24	0	0	3
1142	Non-Reactive	1	23	0	3
1143	Non-Reactive	0	24	0	3
1144	Non-Reactive	0	24	0	3
1145	Reactive	24	0	0	3

Part 1. SCREENING

TABLE 2: Number of Screening Methods Reported; Includes Primary and Secondary Methods

<u>Method Code</u>	<u>Kit Source</u>	<u>Participants</u>
10	Fujirebio Serodia-HIV 1,2	2
11	In House	2
12	Other (Please specify in detail)	3
15	rLAV EIA (Bio-Rad)	5
27	Tecnosuma (Cuba) UMELISA HIV 1+2	3
34	Q-Preven HIV 1+2, DBS, Brazil	1
40	Avioq HIV-1 Microeleisa Systems	8
41	Bio-Rad HIV-1/Hiv-2 plus O EIA	2
		Total 26

**Anti-HIV-1 PT Report
Quarter 1, 2011**

TABLE 3. Quarter 1, 2011, Summary of Errors by Screening Method

Primary and Secondary screens methods	1141		1142		1143		1144		1145	
	FN	IND	FP	IND	FP	IND	FP	IND	FN	IND
10 Fujirebio Serodia-HIV 1,2										
15 Genetic Systems rLAV EIA (Bio-Rad)										
27 Tecnosuma (Cuba) UMELISA HIV 1+2			1							
34 Q-Preven HIV 1+2, DBS, Brazil										
40 Avioq HIV-1 Microeleisa Systems										
41 Bio-Rad HIV-1/Hiv-2 plus O EIA										
11 In House										
12 Other										

False Pos = 1
False Neg = 0
Indeterminant = 0

This **NEWBORN SCREENING QUALITY ASSURANCE PROGRAM** report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
ATLANTA, GA 30341

Director

Thomas R. Frieden, M.D., M.P.H.

Director

National Center for Environmental Health

Christopher J. Portier, Ph.D.

Director

Division of Laboratory Sciences

James L. Pirkle, M.D., Ph.D.

Chief

Newborn Screening and Molecular Biology Branch

Carla Cuthbert, Ph.D.



Contributors: Barbara W. Adam
Brandon Beasley
Carol Bell
Dana Chafin
Paul Dantonio
Sharon Flores
Victor R. De Jesus, Ph.D.
Marie C. Earley, Ph.D.
Tamara Ganka
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.
Joanne Mei, Ph.D.
Nancy Meredith
David Simms
Robert Vogt, Ph.D.
Golriz Yazdanpanah
Hui Zhou, Ph.D.
Sherri Zobel

Production: Sarah Brown
Felicia Manning
Teresa Moore
Connie Singleton

ASSOCIATION OF PUBLIC HEALTH LABORATORIES
SILVER SPRING, MD 20910

President

Patrick F. Luedtke, M.D., M.P.H.

Co-Chairpersons, Newborn Screening and Genetics in Public Health Committee

Cheryl Hermerath, M.B.A., DLM(ASCP), RM(NRCM)

Susan M. Tanksley, Ph.D.

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee

Gary Hoffman, B.S.



INQUIRIES TO:

Carol Bell, Editor • Centers for Disease Control and Prevention (CDC)
Newborn Screening Quality Assurance Program • Mailstop F-43
4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: CBell@cdc.gov